Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00497159
Status:
COMPLETED
Last Update Posted:
2015-06-08
First Post:
2007-07-03
Brief Title:
A Study of the Novel Drug Dimebon in Patients With Huntingtons Disease
Sponsor:
Medivation Inc
Organization:
Medivation Inc
Study Overview
Official Title:
A Multi-Center Phase 2 Randomized Double-Blinded Placebo-Controlled Study of Dimebon in Subjects With Huntingtons Disease
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DIMOND
Brief Summary:
This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive motor and overall function in subjects with Huntingtons Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None